BRAF and non-small cell lung carcinoma: Moreover, in the last decades, there has been a major paradigm shift in the management of metastatic non-small cell lung cancer (NSCLC), with the advent of targeted therapies for patients harbouring druggable alterations such as EGFR or BRAF mutations, as well as ALK, ROS, and RET rearrangements, and so on [7].